- Home
- BBD vs ALNY Comparison
BBD vs ALNY Comparison
Compare BBD & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBD | ALNY |
|---|---|---|
| Founded | 1943 | 2002 |
| Country | Brazil | United States |
| Employees | 80348 | 115 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3B | 38.9B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | BBD | ALNY |
|---|---|---|
| Price | $3.65 | $298.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 28 |
| Target Price | N/A | ★ $471.00 |
| AVG Volume (30 Days) | ★ 35.2M | 1.4M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.82% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | N/A | ★ 2.33 |
| Revenue | N/A | ★ $1,037,418,000.00 |
| Revenue This Year | $70.86 | $52.67 |
| Revenue Next Year | $8.33 | $31.48 |
| P/E Ratio | ★ $9.20 | $133.99 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $2.73 | $273.11 |
| 52 Week High | $4.30 | $495.55 |
Technical Indicators
Market Signals| Indicator | BBD | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 49.98 |
| Support Level | $3.41 | $282.37 |
| Resistance Level | $3.75 | $318.35 |
| Average True Range (ATR) | 0.09 | 15.11 |
| MACD | 0.02 | 2.09 |
| Stochastic Oscillator | 93.94 | 22.28 |
Price Performance
Historical ComparisonAbout BBD Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation, a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.